| 1.11 -0.06 (-5.13%) | 10-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.41 | 1-year : | 1.53 |
| Resists | First : | 1.21 | Second : | 1.3 |
| Pivot price | 1.14 |
|||
| Supports | First : | 1.04 | Second : | 0.87 |
| MAs | MA(5) : | 1.12 |
MA(20) : | 1.14 |
| MA(100) : | 1.47 |
MA(250) : | 2.06 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 47.3 |
D(3) : | 36 |
| RSI | RSI(14): 45.1 |
|||
| 52-week | High : | 3.07 | Low : | 1.04 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SPRO ] has closed above bottom band by 29.9%. Bollinger Bands are 67.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 58 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.17 - 1.17 | 1.17 - 1.18 |
| Low: | 1.1 - 1.1 | 1.1 - 1.11 |
| Close: | 1.1 - 1.11 | 1.11 - 1.12 |
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.
Wed, 28 Oct 2026
This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Tue, 27 Oct 2026
Spero Therapeutics COO Timothy Keutzer to Retire, Provide Transition Advisory Services - TradingView
Tue, 27 Oct 2026
Spero Therapeutics, Inc. (SPRO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Mon, 26 Oct 2026
Spero Therapeutics (NASDAQ:SPRO) Adds Two Leaders as SP001 Development Advances - Kalkine
Mon, 26 Oct 2026
After 11 years, Spero’s COO is set to retire as two executives take new posts. - Stock Titan
Fri, 23 Oct 2026
Spero Therapeutics, Inc. Estimates – NASDAQ:SPRO - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 58 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 22.6 (%) |
| Held by Institutions | 18.3 (%) |
| Shares Short | 795 (K) |
| Shares Short P.Month | 1,210 (K) |
| EPS | 0.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.75 |
| Profit Margin | 15.7 % |
| Operating Margin | 14 % |
| Return on Assets (ttm) | 7.1 % |
| Return on Equity (ttm) | 19.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.45 |
| Sales Per Share | 0.8 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 20 (M) |
| Levered Free Cash Flow | 29 (M) |
| PE Ratio | 7.92 |
| PEG Ratio | 0 |
| Price to Book value | 1.46 |
| Price to Sales | 1.37 |
| Price to Cash Flow | 3.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|